-
Je něco špatně v tomto záznamu ?
SENECA study: staging endometrial cancer based on molecular classification
E. Chacon, F. Boria, RR. Lyer, F. Fanfani, M. Malzoni, P. Bretová, A. Luzarraga Aznar, R. Fruscio, MA. Jedryka, R. Tóth, AM. Perrone, A. Kakkos, I. Cristóbal Quevedo, L. Congedo, V. Zanagnolo, S. Fernandez-Gonzalez, B. Ferro, F. Narducci, T....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, multicentrická studie
NLK
ProQuest Central
od 2018-01-01 do Před 6 měsíci
Health & Medicine (ProQuest)
od 2018-01-01 do Před 6 měsíci
PubMed
39153831
DOI
10.1136/ijgc-2024-005711
Knihovny.cz E-zdroje
- MeSH
- biopsie sentinelové lymfatické uzliny metody MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfatické metastázy MeSH
- nádory endometria * patologie genetika klasifikace MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- sentinelová uzlina patologie MeSH
- staging nádorů * MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
OBJECTIVE: Management of endometrial cancer is advancing, with accurate staging crucial for guiding treatment decisions. Understanding sentinel lymph node (SLN) involvement rates across molecular subgroups is essential. To evaluate SLN involvement in early-stage (International Federation of Gynecology and Obstetrics 2009 I-II) endometrial cancer, considering molecular subtypes and new European Society of Gynaecological Oncology (ESGO) risk classification. METHODS: The SENECA study retrospectively reviewed data from 2139 women with stage I-II endometrial cancer across 66 centers in 16 countries. Patients underwent surgery with SLN assessment following ESGO guidelines between January 2021 and December 2022. Molecular analysis was performed on pre-operative biopsies or hysterectomy specimens. RESULTS: Among the 2139 patients, the molecular subgroups were as follows: 272 (12.7%) p53 abnormal (p53abn, 1191 (55.7%) non-specific molecular profile (NSMP), 581 (27.2%) mismatch repair deficient (MMRd), 95 (4.4%) POLE mutated (POLE-mut). Tracer diffusion was detected in, at least one side, in 97.2% of the cases; with a bilateral diffusion observed in 82.7% of the cases. By ultrastaging (90.7% of the cases) or one-step nucleic acid amplification (198 (9.3%) of the cases), 205 patients were identified with affected sentinel lymph nodes, representing 9.6% of the sample. Of these, 139 (67.8%) had low-volume metastases (including micrometastases, 42.9%; and isolated tumor cells, 24.9%) while 66 (32.2%) had macrometastases. Significant differences in SLN involvement were observed between molecular subtypes, with p53abn and MMRd groups having the highest rates (12.50% and 12.40%, respectively) compared with NSMP (7.80%) and POLE-mut (6.30%), (p=0.004); (p53abn, OR=1.69 (95% CI 1.11 to 2.56), p=0.014; MMRd, OR=1.67 (95% CI 1.21 to 2.31), p=0.002). Differences were also noted among ESGO risk groups (2.84% for low-risk patients, 6.62% for intermediate-risk patients, 21.63% for high-intermediate risk patients, and 22.51% for high-risk patients; p<0.001). CONCLUSIONS: Our study reveals significant differences in SLN involvement among patients with early-stage endometrial cancer based on molecular subtypes. This underscores the importance of considering molecular characteristics for accurate staging and optimal management decisions.
ASST Grande Ospedale Metropolitano Niguarda Milan Italy
Clinic of Obstetrics and Gynecology Hospital San Gerardo Monza Italy
Clinica Universidad de Navarra Pamplona Navarra Spain
Departamento de Ginecologia y Obstetricia Clinica Universidad de Navarra Pamplona Navarra Spain
Department of Gynaecologic Oncology Hospital Universitario 12 de Octubre Madrid Spain
Department of Gynaecology Son Espases University Hospital Palma de Mallorca Spain
Department of Gynecologic Oncology
Department of Gynecologic Oncology Hospital Vall d'Hebron Barcelona Spain
Department of Gynecologic Oncology Nairi Medical Center Yerevan Armenia
Department of Gynecologic Oncology Universidad de Navarra Pamplona Navarra Spain
Department of Gynecologic Oncology University Hospital La Fe Valencia Valencia Spain
Department of Gynecological Oncology Wroclaw Medical University Wroclaw Poland
Department of Gynecology and Obstetrics Mauriziano Hospital Torino Italy
Department of Gynecology Centre Oscar Lambret Lille France
Department of Gynecology Clinica Universidad de Navarra Pamplona Navarra Spain
Department of Medical Oncology Clinica Universidad de Navarra Madrid Spain
Department of Medicine and Surgery University of Milan Bicocca Milano Italy
Department of Obstetrics and Gynaecology Clinico Lozano Blesa Hospital Zaragoza Spain
Department of Obstetrics and Gynaecology Semmelweis University Budapest Hungary
Department of Obstetrics and Gynecology Bezmialem Vakif Universitesi Istanbul Istanbul Turkey
Department of Obstetrics and Gynecology Brno University Hospital Brno Czech Republic Czech Republic
Department of Obstetrics and Gynecology CHU de Liège Liege Belgium
Department of Obstetrics and Gynecology Fundación Instituto Valenciano de Oncologia Valencia Spain
Department of Obstetrics and Gynecology Hospital Lariboisière Paris France
Department of Obstetrics and Gynecology La Paz University Hospital Madrid Madrid Spain
Department of Oncological Gynecology Lower Silesian Oncology Center Wrocław Wroclaw Poland
Department of Woman and Child Health Sciences University Hospital Agostino Gemelli Roma Lazio Italy
Holycross Cancer Center Kielce Poland
Hospital Universitari Dexeus Barcelona Catalunya Spain
Hospital Universitario Nuestra Senora de la Candelaria Santa Cruz de Tenerife Spain
Istanbul University Cerrahpasa Cerrahpasa Faculty of Medicine Fatih Istanbul Turkey
Istituto Europeo di Oncologia Milano Anognnn Italy
Obstetrics and Gynecology University Hospitals Leuven Leuven Vlaams Brabant Belgium
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019014
- 003
- CZ-PrNML
- 005
- 20241024111133.0
- 007
- ta
- 008
- 241015s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1136/ijgc-2024-005711 $2 doi
- 035 __
- $a (PubMed)39153831
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Chacon, Enrique $u Department of Gynecologic Oncology, Universidad de Navarra, Pamplona, Navarra, Spain echaconc@unav.es $1 https://orcid.org/0000000186598602
- 245 10
- $a SENECA study: staging endometrial cancer based on molecular classification / $c E. Chacon, F. Boria, RR. Lyer, F. Fanfani, M. Malzoni, P. Bretová, A. Luzarraga Aznar, R. Fruscio, MA. Jedryka, R. Tóth, AM. Perrone, A. Kakkos, I. Cristóbal Quevedo, L. Congedo, V. Zanagnolo, S. Fernandez-Gonzalez, B. Ferro, F. Narducci, T. Hovhannisyan, E. Aksahin, L. Cardenas, MR. Oliver, G. Nozaleda, M. Arnaez, M. Misiek, A. Ferrero, FA. Pain, J. Zarragoitia, C. Diaz, L. Ceppi, S. Mehdiyev, F. Roldán-Rivas, AR. Guijarro-Campillo, J. Amengual, N. Manzour, L. Sanchez Lorenzo, JM. Núñez-Córdoba, A. Gonzalez Martin, JA. Minguez, L. Chiva, SENECA Working Group
- 520 9_
- $a OBJECTIVE: Management of endometrial cancer is advancing, with accurate staging crucial for guiding treatment decisions. Understanding sentinel lymph node (SLN) involvement rates across molecular subgroups is essential. To evaluate SLN involvement in early-stage (International Federation of Gynecology and Obstetrics 2009 I-II) endometrial cancer, considering molecular subtypes and new European Society of Gynaecological Oncology (ESGO) risk classification. METHODS: The SENECA study retrospectively reviewed data from 2139 women with stage I-II endometrial cancer across 66 centers in 16 countries. Patients underwent surgery with SLN assessment following ESGO guidelines between January 2021 and December 2022. Molecular analysis was performed on pre-operative biopsies or hysterectomy specimens. RESULTS: Among the 2139 patients, the molecular subgroups were as follows: 272 (12.7%) p53 abnormal (p53abn, 1191 (55.7%) non-specific molecular profile (NSMP), 581 (27.2%) mismatch repair deficient (MMRd), 95 (4.4%) POLE mutated (POLE-mut). Tracer diffusion was detected in, at least one side, in 97.2% of the cases; with a bilateral diffusion observed in 82.7% of the cases. By ultrastaging (90.7% of the cases) or one-step nucleic acid amplification (198 (9.3%) of the cases), 205 patients were identified with affected sentinel lymph nodes, representing 9.6% of the sample. Of these, 139 (67.8%) had low-volume metastases (including micrometastases, 42.9%; and isolated tumor cells, 24.9%) while 66 (32.2%) had macrometastases. Significant differences in SLN involvement were observed between molecular subtypes, with p53abn and MMRd groups having the highest rates (12.50% and 12.40%, respectively) compared with NSMP (7.80%) and POLE-mut (6.30%), (p=0.004); (p53abn, OR=1.69 (95% CI 1.11 to 2.56), p=0.014; MMRd, OR=1.67 (95% CI 1.21 to 2.31), p=0.002). Differences were also noted among ESGO risk groups (2.84% for low-risk patients, 6.62% for intermediate-risk patients, 21.63% for high-intermediate risk patients, and 22.51% for high-risk patients; p<0.001). CONCLUSIONS: Our study reveals significant differences in SLN involvement among patients with early-stage endometrial cancer based on molecular subtypes. This underscores the importance of considering molecular characteristics for accurate staging and optimal management decisions.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a nádory endometria $x patologie $x genetika $x klasifikace $7 D016889
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a staging nádorů $7 D009367
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a sentinelová uzlina $x patologie $7 D000071036
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a biopsie sentinelové lymfatické uzliny $x metody $7 D021701
- 650 _2
- $a lymfatické metastázy $7 D008207
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Boria, Felix $u Hospital Universitario Nuestra Senora de la Candelaria, Santa Cruz de Tenerife, Spain $1 https://orcid.org/0000000247616190
- 700 1_
- $a Lyer, R Rajagopalan $u Department of Gynecologic Oncology, Basavatarakam Indo-American Cancer Institute and Research Centre, Hyderabad, Telangana, India $1 https://orcid.org/000000022178134X
- 700 1_
- $a Fanfani, Francesco $u Department of Women, Children and Public Health Sciences, Gynecologic Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- 700 1_
- $a Malzoni, Mario $u Endoscopica Malzoni, Center for Advanced Endoscopic Gynecologic Surgery, Center for Advanced Endoscopic Gynecologic Surgery, Avellino, Italy
- 700 1_
- $a Bretová, Petra $u Department of Obstetrics and Gynecology, Brno University Hospital, Brno, Czech Republic, Czech Republic $1 https://orcid.org/000000031082433X
- 700 1_
- $a Luzarraga Aznar, Ana $u Department of Gynecologic Oncology, Hospital Vall d'Hebron, Barcelona, Spain $1 https://orcid.org/0000000160070308
- 700 1_
- $a Fruscio, Robert $u Department of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy $u Clinic of Obstetrics and Gynecology, Hospital San Gerardo, Monza, Italy $1 https://orcid.org/0000000156882194
- 700 1_
- $a Jedryka, Marcin A $u Department of Oncological Gynecology, Lower Silesian Oncology Center Wrocław, Wroclaw, Poland $u Department of Gynecological Oncology, Wroclaw Medical University, Wroclaw, Poland $1 https://orcid.org/0000000189350311
- 700 1_
- $a Tóth, Richard $u Department of Obstetrics and Gynaecology, Semmelweis University, Budapest, Hungary $1 https://orcid.org/0009000095355821
- 700 1_
- $a Perrone, Anna Myriam $u Universitaria di Bologna, Bologna, Italy $1 https://orcid.org/0000000331404772
- 700 1_
- $a Kakkos, Athanasios $u Department of Obstetrics and Gynecology, CHU de Liège, Liege, Belgium
- 700 1_
- $a Cristóbal Quevedo, Ignacio $u Department of Obstetrics and Gynecology, La Paz University Hospital, Madrid, Madrid, Spain $1 https://orcid.org/000000033276231X
- 700 1_
- $a Congedo, Luigi $u Department of Woman and Child Health Sciences, University Hospital Agostino Gemelli, Roma, Lazio, Italy $u Department of Gynecologic Oncology; Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium
- 700 1_
- $a Zanagnolo, Vanna $u Istituto Europeo di Oncologia, Milano, Anognnn, Italy
- 700 1_
- $a Fernandez-Gonzalez, Sergi $u Department of Gynecology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain $1 https://orcid.org/0000000291386978
- 700 1_
- $a Ferro, Beatriz $u Department of Obstetrics and Gynecology, Centro Hospitalar e Universitário de Coimbra EPE, Coimbra, Coimbra, Portugal
- 700 1_
- $a Narducci, Fabrice $u Department of Gynecology, Centre Oscar Lambret, Lille, France
- 700 1_
- $a Hovhannisyan, Tatevik $u Department of Gynecologic Oncology, Nairi Medical Center, Yerevan, Armenia
- 700 1_
- $a Aksahin, Elif $u Istanbul University-Cerrahpasa Cerrahpasa Faculty of Medicine, Fatih, Istanbul, Turkey
- 700 1_
- $a Cardenas, Laura $u Gynecologic Oncology Unit, Hospital Universitario de Girona Doctor Josep Trueta, Girona, Catalunya, Spain
- 700 1_
- $a Oliver, M Reyes $u Department of Gynaecologic Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain
- 700 1_
- $a Nozaleda, Gonzalo $u Department of Obstetrics and Gynecology, Hospital General Universitario Gregorio Marañón, Madrid, Madrid, Spain
- 700 1_
- $a Arnaez, Marta $u Department of Gynecologic Oncology, University Hospital La Fe, Valencia, Valencia, Spain $1 https://orcid.org/0000000327067865
- 700 1_
- $a Misiek, Marcin $u Holycross Cancer Center, Kielce, Poland
- 700 1_
- $a Ferrero, Annamaria $u Department of Gynecology and Obstetrics, Mauriziano Hospital, Torino, Italy
- 700 1_
- $a Pain, Flore Anne $u Department of Obstetrics and Gynecology, Hospital Lariboisière, Paris, France
- 700 1_
- $a Zarragoitia, Janire $u Hospital Universitari Dexeus, Barcelona, Catalunya, Spain
- 700 1_
- $a Diaz, Cristina $u Department of Obstetrics and Gynecology, Fundación Instituto Valenciano de Oncologia, Valencia, Spain
- 700 1_
- $a Ceppi, Lorenzo $u ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
- 700 1_
- $a Mehdiyev, Shamsi $u Department of Obstetrics and Gynecology, Bezmialem Vakif Universitesi, Istanbul, Istanbul, Turkey
- 700 1_
- $a Roldán-Rivas, Fernando $u Department of Obstetrics and Gynaecology, Clinico Lozano Blesa Hospital, Zaragoza, Spain $u Universitat de Barcelona, Barcelona, Spain
- 700 1_
- $a Guijarro-Campillo, Alberto Rafael $u Department of Obstetrics and Gynecology, Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Spain $1 https://orcid.org/0000000228319975
- 700 1_
- $a Amengual, Joana $u Department of Gynaecology, Son Espases University Hospital, Palma de Mallorca, Spain $1 https://orcid.org/0000000225966819
- 700 1_
- $a Manzour, Nabil $u Departamento de Ginecologia y Obstetricia, Clinica Universidad de Navarra, Pamplona, Navarra, Spain $1 https://orcid.org/0000000246046042
- 700 1_
- $a Sanchez Lorenzo, Luisa $u Department of Medical Oncology, Clinica Universidad de Navarra, Madrid, Spain $1 https://orcid.org/0000000191396730
- 700 1_
- $a Núñez-Córdoba, Jorge M $u Clinica Universidad de Navarra, Pamplona, Navarra, Spain
- 700 1_
- $a Gonzalez Martin, Antonio $u Department of Medical Oncology, Clinica Universidad de Navarra, Madrid, Spain $1 https://orcid.org/0000000183769576
- 700 1_
- $a Minguez, Jose Angel $u Department of Gynecology, Clinica Universidad de Navarra, Pamplona, Navarra, Spain $1 https://orcid.org/0000000336358920
- 700 1_
- $a Chiva, Luis $u Departamento de Ginecologia y Obstetricia, Clinica Universidad de Navarra, Pamplona, Navarra, Spain $1 https://orcid.org/0000000219083251
- 710 2_
- $a SENECA Working Group
- 773 0_
- $w MED00009896 $t International journal of gynecological cancer : official journal of the International Gynecological Cancer Society $x 1525-1438 $g Roč. 34, č. 9 (2024), s. 1313-1321
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39153831 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111127 $b ABA008
- 999 __
- $a ok $b bmc $g 2201692 $s 1230987
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 34 $c 9 $d 1313-1321 $e 20240902 $i 1525-1438 $m International journal of gynecological cancer : official journal of the International Gynecological Cancer Society $n Int J Gynecol Cancer $x MED00009896
- LZP __
- $a Pubmed-20241015
